Bone health in patients with multiple sclerosis.

Vit Zikan
Author Information
  1. Vit Zikan: Department of Internal Medicine 3, Faculty of Medicine 1, Charles University, 128 00 Prague, Czech Republic.

Abstract

Multiple sclerosis (MS) is a gait disorder characterized by acute episodes of neurological defects leading to progressive disability. Patients with MS have multiple risk factors for osteoporotic fractures, such as progressive immobilization, long-term glucocorticoids (GCs) treatment or vitamin D deficiency. The duration of motor disability appears to be a major contributor to the reduction of bone strength. The long term immobilization causes a marked imbalance between bone formation and resorption with depressed bone formation and a marked disruption of mechanosensory network of tightly connected osteocytes due to increase of osteocyte apoptosis. Patients with higher level of disability have also higher risk of falls that combined with a bone loss increases the frequency of bone fractures. There are currently no recommendations how to best prevent and treat osteoporosis in patients with MS. However, devastating effect of immobilization on the skeleton in patients with MS underscores the importance of adequate mechanical stimuli for maintaining the bone structure and its mechanical competence. The physical as well as pharmacological interventions which can counteract the bone remodeling imbalance, particularly osteocyte apoptosis, will be promising for prevention and treatment of osteoporosis in patients with MS.

References

  1. Eur J Endocrinol. 2006 May;154(5):745-51 [PMID: 16645023]
  2. Endocrinology. 2006 Dec;147(12):5592-9 [PMID: 16935844]
  3. Clin Rheumatol. 1989 Jun;8 Suppl 2:95-103 [PMID: 2667875]
  4. J Bone Miner Res. 2003 Dec;18(12):2083-94 [PMID: 14672343]
  5. Ir J Med Sci. 2009 Mar;178(1):43-5 [PMID: 19002746]
  6. Eur J Neurol. 2008 Sep;15(9):916-21 [PMID: 18637953]
  7. Osteoporos Int. 2010 Sep;21(9):1457-69 [PMID: 20204595]
  8. Rheumatology (Oxford). 2000 Dec;39(12):1383-9 [PMID: 11136882]
  9. Mult Scler. 2004 Apr;10(2):170-5 [PMID: 15124763]
  10. Clin Chim Acta. 2004 Oct;348(1-2):147-54 [PMID: 15369748]
  11. Arthritis Rheum. 2009 Nov;60(11):3346-55 [PMID: 19877063]
  12. Ned Tijdschr Geneeskd. 2008 Oct 25;152(43):2357-60 [PMID: 19024069]
  13. Osteoporos Int. 2002 Oct;13(10):777-87 [PMID: 12378366]
  14. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003980 [PMID: 15674920]
  15. J Bone Miner Metab. 2005;23(4):309-13 [PMID: 15981027]
  16. J Med Invest. 2001 Aug;48(3-4):147-56 [PMID: 11694954]
  17. Arch Phys Med Rehabil. 2008 Feb;89(2):237-43 [PMID: 18226646]
  18. Bone. 2010 Jan;46(1):4-12 [PMID: 19591966]
  19. Biochem Pharmacol. 2009 Jun 15;77(12):1757-62 [PMID: 19428330]
  20. Calcif Tissue Int. 2008 Apr;82(4):249-57 [PMID: 18414920]
  21. Bone. 2005 Feb;36(2):331-9 [PMID: 15780960]
  22. Calcif Tissue Int. 1997 Aug;61(2):129-33 [PMID: 9236259]
  23. Am J Phys Med Rehabil. 2010 Jun;89(6):446-57 [PMID: 20216060]
  24. Nature. 2009 Mar 26;458(7237):524-8 [PMID: 19204730]
  25. Biochem Biophys Res Commun. 2010 Nov 12;402(2):173-6 [PMID: 20920469]
  26. Nat Rev Immunol. 2009 Jun;9(6):440-7 [PMID: 19444308]
  27. Crit Rev Oral Biol Med. 2004 Jun 04;15(3):126-36 [PMID: 15187031]
  28. Arch Intern Med. 2007 Jun 25;167(12):1240-5 [PMID: 17592096]
  29. J Bone Miner Res. 2004 Jul;19(7):1067-74 [PMID: 15176988]
  30. Phys Med Rehabil Clin N Am. 1998 Aug;9(3):603-14, vii [PMID: 9894112]
  31. Lancet. 2008 Oct 25;372(9648):1502-17 [PMID: 18970977]
  32. J Endocrinol Invest. 2008 Jul;31(7 Suppl):53-8 [PMID: 18791353]
  33. Clin Neurol Neurosurg. 2002 Jul;104(3):182-91 [PMID: 12127652]
  34. Osteoporos Int. 2011 Jan;22(1):271-9 [PMID: 20358358]
  35. Osteoporos Int. 2006 Feb;17(2):180-92 [PMID: 16217589]
  36. J Bone Miner Res. 2010 Apr;25(4):734-45 [PMID: 19821772]
  37. J Neuroimmunol. 2005 Jan;158(1-2):231-9 [PMID: 15589058]
  38. Biochem Biophys Res Commun. 2004 Aug 6;320(4):1163-8 [PMID: 15249211]
  39. Bone. 2008 Jul;43(1):149-155 [PMID: 18467202]
  40. Int Rev Neurobiol. 2008;83:305-28 [PMID: 18929090]
  41. J Bone Miner Res. 2009 Dec;24(12):1998-2006 [PMID: 19453263]
  42. Bone. 2009 May;44(5):734-43 [PMID: 19195497]
  43. Eur J Clin Invest. 1990 Jun;20(3):330-5 [PMID: 2114994]
  44. Mult Scler. 2003 Dec;9(6):600-4 [PMID: 14664473]
  45. Mult Scler. 2010 Sep;16(9):1031-43 [PMID: 20551086]
  46. J Clin Endocrinol Metab. 2004 Oct;89(10):4923-8 [PMID: 15472186]
  47. Osteoporos Int. 2005 Mar;16(3):263-72 [PMID: 15338112]
  48. J Neurol Sci. 2009 Jan 15;276(1-2):41-4 [PMID: 18845306]
  49. J Bone Miner Res. 2006 Apr;21(4):605-15 [PMID: 16598381]
  50. Drug Saf. 2007;30(2):171-84 [PMID: 17253881]
  51. Calcif Tissue Int. 1991 Feb;48(2):93-100 [PMID: 2013018]
  52. Eur J Neurol. 2005 Jul;12(7):550-6 [PMID: 15958096]
  53. J Musculoskelet Neuronal Interact. 2010 Jun;10(2):128-35 [PMID: 20516629]
  54. Mult Scler. 2008 Apr;14(3):431-2 [PMID: 18208894]
  55. Osteoporos Int. 1997;7 Suppl 3:S63-7 [PMID: 9536305]
  56. Curr Neurol Neurosci Rep. 2010 Sep;10(5):407-12 [PMID: 20567946]
  57. Bone. 2010 Sep;47(3):604-9 [PMID: 20601295]
  58. J Bone Miner Metab. 2009;27(5):574-83 [PMID: 19333678]
  59. Neurology. 1998 Oct;51(4):1161-5 [PMID: 9781548]
  60. Curr Osteoporos Rep. 2010 Dec;8(4):185-91 [PMID: 20809204]
  61. J Clin Densitom. 2008 Oct-Dec;11(4):511-7 [PMID: 18639477]
  62. Bone. 2010 Mar;46(3):564-70 [PMID: 19591965]
  63. Bone. 2007 Nov;41(5):745-51 [PMID: 17855178]
  64. Autoimmun Rev. 2010 Sep;9(11):709-15 [PMID: 20601202]
  65. Neurology. 1994 Sep;44(9):1687-92 [PMID: 7936297]
  66. J Bone Miner Res. 2007 Jan;22(1):64-71 [PMID: 17042715]
  67. Crit Rev Eukaryot Gene Expr. 2009;19(3):219-33 [PMID: 19883366]
  68. Endocr Rev. 2007 Apr;28(2):151-64 [PMID: 17200084]
  69. Arch Neurol. 2008 Feb;65(2):232-5 [PMID: 18268193]
  70. Lancet Neurol. 2010 Jun;9(6):599-612 [PMID: 20494325]
  71. Bone. 2005 Sep;37(3):287-95 [PMID: 16006205]
  72. Mult Scler. 2011 Jan;17(1):32-42 [PMID: 20921238]
  73. J Bone Miner Res. 2004 Jan;19(1):48-55 [PMID: 14753736]
  74. Arch Neurol. 1996 Aug;53(8):753-7 [PMID: 8759981]
  75. Clin Endocrinol (Oxf). 2010 Sep;73(3):277-85 [PMID: 20796001]
  76. Eur J Endocrinol. 2005 Feb;152(2):199-205 [PMID: 15745926]
  77. Bone. 2006 Aug;39(2):253-9 [PMID: 16574519]
  78. Cell Metab. 2007 Jun;5(6):464-75 [PMID: 17550781]
  79. N Engl J Med. 2006 May 25;354(21):2250-61 [PMID: 16723616]
  80. Bone. 2011 Feb;48(2):197-201 [PMID: 20850580]
  81. J Bone Miner Res. 2009 Oct;24(10):1651-61 [PMID: 19419300]
  82. Arch Intern Med. 2007 Jun 25;167(12):1246-51 [PMID: 17592097]
  83. J Rehabil Med. 2010 Oct;42(9):866-72 [PMID: 20878048]
  84. Arthritis Rheum. 2007 Jan;56(1):208-14 [PMID: 17195223]
  85. Endocrinol Metab Clin North Am. 2010 Jun;39(2):381-400, table of contents [PMID: 20511059]
  86. J Orthop Res. 2009 Nov;27(11):1521-7 [PMID: 19437511]
  87. Neurology. 2009 Oct 27;73(17):1394-8 [PMID: 19858462]

Word Cloud

Created with Highcharts 10.0.0boneMSpatientsdisabilityimmobilizationsclerosisprogressivePatientsmultipleriskfracturestreatmentmarkedimbalanceformationosteocyteapoptosishigherosteoporosismechanicalMultiplegaitdisordercharacterizedacuteepisodesneurologicaldefectsleadingfactorsosteoporoticlong-termglucocorticoidsGCsvitaminDdeficiencydurationmotorappearsmajorcontributorreductionstrengthlongtermcausesresorptiondepresseddisruptionmechanosensorynetworktightlyconnectedosteocytesdueincreaselevelalsofallscombinedlossincreasesfrequencycurrentlyrecommendationsbestpreventtreatHoweverdevastatingeffectskeletonunderscoresimportanceadequatestimulimaintainingstructurecompetencephysicalwellpharmacologicalinterventionscancounteractremodelingparticularlywillpromisingpreventionBonehealth

Similar Articles

Cited By